Response to ‘Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after PD1 inhibition with nivolumab’

Abstract

We thank Dr. Fung and colleagues for their interest in our publication concerning eruptive keratoacanthomas (KAs) and bullous pemphigoid-like disease in patients on anti-programmed cell death-1 (PD-1) immunotherapy.¹ We agree that nivolumab, like pembrolizumab, seems to share the same immune-related adverse event profile, and in fact our second case occurred in a patient on nivolumab (after no visible reduction in metastatic disease on pembrolizumab).

This article is protected by copyright. All rights reserved.

http://ift.tt/2fhmNsC